Recombinant Brucella suis Glucose-6-phosphate isomerase (pgi), partial

What is the functional role of glucose-6-phosphate isomerase in Brucella suis metabolism?

Glucose-6-phosphate isomerase (PGI) catalyzes the reversible isomerization of glucose-6-phosphate to fructose-6-phosphate, representing a critical connection point between different metabolic pathways. Although Brucella species lack classical glycolysis, PGI plays an important role in connecting carbohydrate metabolism pathways. In B. suis biovar 5, glucose can be metabolized through both the Pentose Phosphate pathway and the Entner-Doudoroff pathway . PGI enables the interconversion that directs glucose-derived carbon between these different pathways, facilitating metabolic flexibility during host infection and environmental adaptation.

Why is PGI considered important for B. suis virulence?

PGI is considered significant for B. suis virulence due to its pleiotropic effects beyond simple carbon metabolism. A 3 log CFU attenuation was observed in a B. suis 1330 P-glucose isomerase (pgi) Tn5 mutant . Importantly, PGI mutation affects not only central carbon metabolism but also the synthesis of mannose and hexosamine, two sugars required for lipopolysaccharide (LPS) building . Since LPS is a critical virulence factor for Brucella, PGI's contribution to virulence is likely multifaceted, involving both metabolic functions and cell envelope biogenesis.

How do the biochemical properties of bacterial PGI enzymes compare?

While B. suis PGI-specific parameters are not fully characterized in the literature, comparison with other bacterial PGI enzymes provides valuable insights. Recombinant Mycobacterium tuberculosis PGI has a molecular mass of 61.45 kDa, specific activity of 600 U/mg protein, and optimal activity at 37°C and pH 9.0 . Additionally, M. tuberculosis PGI has a Km of 0.318 mM for fructose-6-phosphate and a Ki of 0.8 mM for 6-phosphogluconate . Unlike some enzymes, it does not require mono- or divalent cations for activity . These properties provide a reference framework for characterizing B. suis PGI.

How is the pgi gene organized in the B. suis genome?

The pgi gene in B. suis is likely part of an operon involved in carbohydrate metabolism, though specific details about its genomic organization are not provided in the search results. Research shows that mutations in pgi have pleiotropic effects , suggesting that its expression may be coordinated with other genes involved in both central carbon metabolism and cell envelope synthesis. Researchers investigating pgi should analyze its genomic context, including upstream regulatory elements and neighboring genes, to understand its coordinated expression with related metabolic functions.

What expression systems are most effective for producing recombinant B. suis PGI?

Based on successful expression of other bacterial PGIs and Brucella proteins, Escherichia coli-based expression systems using T7 promoter vectors (such as pET series) are likely most effective for B. suis PGI expression. For M. tuberculosis PGI, the pET-22b(+) vector with E. coli as the expression host proved successful . Key considerations for optimizing expression include:

• Testing various E. coli strains (BL21(DE3), Rosetta, Arctic Express)

• Optimizing induction conditions (IPTG concentration, temperature, duration)

• Including solubility-enhancing fusion tags (His, MBP, GST)

• Addressing potential toxicity through regulated expression systems

• Codon optimization if expression levels are suboptimal

What challenges are commonly encountered during recombinant B. suis PGI expression?

Expression of recombinant B. suis PGI likely faces several challenges similar to those observed with other bacterial enzymes. The recombinant M. tuberculosis PGI expressed partly as soluble protein and partly as inclusion bodies , suggesting similar issues may arise with B. suis PGI. Common challenges include:

• Formation of insoluble inclusion bodies due to protein misfolding

• Low expression yields due to codon bias or toxicity

• Loss of enzymatic activity during purification processes

• Protein instability in standard buffer conditions

• Co-purification of contaminating bacterial proteins with similar properties

• Maintaining proper oligomeric structure (likely dimeric)

What purification strategy yields highest activity for recombinant B. suis PGI?

A multi-step purification approach is recommended to obtain highly pure and active recombinant B. suis PGI:

• Affinity chromatography (if using tagged protein) as initial capture step

• Ion-exchange chromatography (as successfully used for M. tuberculosis PGI)

• Size exclusion chromatography as final polishing step

Critical factors for maintaining activity include:

• Using appropriate buffer systems (likely phosphate or Tris at pH 7.5-8.5)

• Including stabilizing agents such as glycerol (10-20%)

• Adding reducing agents to prevent oxidation of thiol groups

• Minimizing time between purification steps

• Avoiding repeated freeze-thaw cycles

• Monitoring enzyme activity at each purification stage

How can solubility of recombinant B. suis PGI be improved?

Multiple strategies can enhance solubility of recombinant B. suis PGI:

• Lower induction temperature (16-20°C instead of 37°C)

• Reduced IPTG concentration (0.1-0.5 mM)

• Co-expression with molecular chaperones (GroEL/GroES, DnaK/DnaJ)

• Use of solubility-enhancing fusion partners (MBP, GST, SUMO)

• Addition of compatible solutes to growth media (sorbitol, glycine betaine)

• Optimization of lysis buffer composition (salt concentration, pH, mild detergents)

• Expression in specialized E. coli strains designed for improved protein folding

What are the optimal methods for assessing recombinant B. suis PGI activity?

Several complementary approaches can be used to characterize recombinant B. suis PGI activity:

• Direct spectrophotometric assay: Measure the isomerization reaction using coupled enzyme systems that link PGI activity to NAD(P)H production/consumption.

• Enzyme kinetics determination:

  • Measure initial reaction rates at varying substrate concentrations

  • Determine key parameters: Km, Vmax, kcat, and kcat/Km for both forward and reverse reactions

  • Assess pH profile (likely optimal around pH 9.0 based on M. tuberculosis PGI)

  • Determine temperature optimum (expected around 37°C)

• Inhibition studies:

  • Test sensitivity to known PGI inhibitors like 6-phosphogluconate (Ki = 0.8 mM for M. tuberculosis PGI)

  • Evaluate product inhibition characteristics

  • Screen for novel inhibitors specific to B. suis PGI

How can researchers verify the structural integrity of purified recombinant B. suis PGI?

Multiple biophysical and biochemical techniques should be employed to verify structural integrity:

• Size exclusion chromatography to confirm expected oligomeric state (likely dimeric)

• Circular dichroism spectroscopy to assess secondary structure composition

• Thermal shift assays to determine protein stability and effects of buffer conditions

• Mass spectrometry to confirm protein identity and detect any modifications

• Dynamic light scattering to evaluate homogeneity and detect aggregation

• Limited proteolysis to probe for properly folded tertiary structure

• Activity assays correlating with structural characteristics

What factors affect stability of recombinant B. suis PGI?

Multiple factors can impact the stability of recombinant B. suis PGI:

• Temperature: Stability decreases at temperatures above physiological range

• pH extremes: Likely most stable near its optimal pH for activity (around pH 9.0 based on M. tuberculosis PGI)

• Oxidation: Exposed cysteine residues may form inappropriate disulfide bonds

• Proteolytic degradation: Sensitivity to contaminating proteases

• Buffer composition: Ionic strength, specific ions, and buffer type all impact stability

• Protein concentration: Dilute solutions may promote subunit dissociation

• Storage conditions: Repeated freeze-thaw cycles accelerate denaturation

• Presence of substrates or inhibitors: May enhance stability through conformational effects

How do mutations in key residues affect B. suis PGI activity?

Site-directed mutagenesis of key residues can provide insights into B. suis PGI structure-function relationships:

• Catalytic residues: Mutations in predicted active site residues would be expected to severely reduce or eliminate activity

• Substrate binding residues: Alterations may affect Km values and substrate specificity

• Dimer interface residues: Mutations could disrupt oligomeric structure and reduce activity

• Regulatory sites: Modifications may alter allosteric regulation or response to inhibitors

• Stabilizing residues: Changes could affect thermal stability or resistance to denaturation

These studies require:

• Structural analysis or homology modeling to identify key residues

• Creation of mutant variants through site-directed mutagenesis

• Expression and purification of mutant proteins

• Systematic comparison of biochemical properties with wild-type enzyme

How does the pgi mutation affect B. suis virulence in experimental models?

The pgi mutation significantly impacts B. suis virulence. A B. suis 1330 pgi Tn5 mutant showed a 3 log CFU attenuation in virulence models . This substantial reduction likely results from multiple effects:

• Disrupted carbohydrate metabolism affecting energy production

• Altered synthesis of mannose and hexosamine, which are required for lipopolysaccharide building

• Potential impacts on stress response mechanisms within host cells

• Changes in expression of other virulence factors

Can recombinant B. suis PGI serve as a diagnostic antigen for brucellosis?

While the diagnostic potential of B. suis PGI has not been directly investigated, insights can be drawn from other Brucella proteins. Outer membrane and periplasmic proteins of Brucella have shown promise as diagnostic antigens . For recombinant B. suis PGI to be valuable as a diagnostic antigen, several factors must be considered:

• Immunogenicity: Whether PGI elicits strong antibody responses during natural infection

• Specificity: Potential cross-reactivity with PGI from other bacteria

• Conservation: Sequence variability across Brucella species and strains

• Accessibility: Whether primarily cytoplasmic PGI is exposed to the immune system

• Diagnostic performance: Sensitivity and specificity in various test formats

• Differentiation potential: Ability to distinguish infected from vaccinated animals

Current research indicates that outer membrane proteins like BP26 (Omp28) show greater promise as diagnostic antigens than cytoplasmic enzymes .

How can recombinant B. suis PGI contribute to understanding Brucella metabolism during infection?

Recombinant B. suis PGI can provide numerous insights into Brucella metabolism during infection:

• Characterize enzymatic properties under conditions mimicking the intracellular environment

• Identify potential metabolic adaptations specific to host cell niches

• Determine if PGI is regulated by host-derived signals or stress conditions

• Investigate interactions with other Brucella metabolic enzymes

• Study the effects of metabolic inhibitors on PGI activity

• Compare properties with PGI from other Brucella species to understand host adaptation

• Enable metabolic flux analysis by providing enzyme parameters for computational models

Understanding these aspects is particularly important given that Brucella's intracellular lifestyle likely involves significant metabolic adaptation, with evidence suggesting they use mostly 3 and 4 carbon substrates rather than hexoses within host cells .

What is the potential of B. suis PGI as a target for antimicrobial development?

Several characteristics make B. suis PGI a potential target for antimicrobial development:

• Importance for virulence: The 3 log CFU attenuation of the pgi mutant indicates its significance for infection.

• Pleiotropic effects: PGI impacts both metabolism and cell envelope synthesis , making resistance development through alternative pathways less likely.

• Drug discovery approach:

  • High-throughput screening using purified recombinant enzyme

  • Structure-based drug design if crystal structure becomes available

  • Fragment-based approaches targeting the active site

  • Repurposing of existing PGI inhibitors from other research areas

• Challenges:

  • Achieving selectivity over mammalian PGI to minimize toxicity

  • Ensuring compound penetration into Brucella cells

  • Demonstrating efficacy in cellular and animal models

  • Addressing potential metabolic bypasses

How can systems biology approaches integrate PGI function into broader B. suis metabolic networks?

Systems biology approaches can provide comprehensive understanding of PGI's role in B. suis metabolism:

• Multi-omics integration:

  • Transcriptomics: Gene expression changes in wild-type vs. pgi mutants

  • Proteomics: Protein abundance and interaction networks involving PGI

  • Metabolomics: Metabolite profiles affected by PGI activity

  • Fluxomics: Carbon flow through central metabolic pathways

• Computational modeling:

  • Genome-scale metabolic models incorporating PGI kinetic parameters

  • Flux balance analysis to predict effects of PGI inhibition

  • Identification of synthetic lethal interactions with PGI

  • Host-pathogen interaction models incorporating metabolic exchange

• Experimental validation:

  • Creation of reporter strains to monitor metabolic states in vitro and in vivo

  • Isotope labeling experiments to track carbon flow

  • Conditional PGI expression systems to study temporal requirements

What structural biology approaches can elucidate B. suis PGI function?

Advanced structural biology techniques can provide critical insights into B. suis PGI:

How can comparative studies across Brucella species inform PGI evolution and adaptation?

Comparative analysis of PGI across Brucella species can reveal evolutionary adaptations:

• Sequence analysis:

  • Phylogenetic comparison of PGI sequences across Brucella species and biovars

  • Identification of conserved catalytic residues versus variable regions

  • Detection of selection signatures indicating adaptive evolution

  • Correlation with host preference and pathogenicity patterns

• Functional comparisons:

  • Expression and characterization of PGI from multiple Brucella species

  • Comparison of kinetic parameters, substrate specificity, and inhibition profiles

  • Cross-complementation studies in pgi mutant backgrounds

  • Assessment of thermal stability and pH optima as indicators of niche adaptation

• Genomic context:

  • Analysis of pgi gene neighborhood across species

  • Investigation of regulatory elements controlling expression

  • Correlation with presence/absence of alternative metabolic pathways

What methodologies can determine the role of PGI in B. suis biofilm formation and persistence?

Several approaches can investigate PGI's potential role in biofilm formation and persistence:

• Biofilm models:

  • Comparison of wild-type and pgi mutant strains in biofilm formation assays

  • Analysis of extracellular polysaccharide composition and structure

  • Evaluation of biofilm architecture using confocal microscopy

  • Testing resistance to antimicrobials and stress conditions

• Persistence studies:

  • Long-term survival assays under nutrient limitation

  • Stress response activation in wild-type versus pgi mutants

  • Metabolic activity measurements in dormant/persistent states

  • Single-cell analysis of PGI expression in different subpopulations

• In vivo relevance:

  • Chronic infection models to assess long-term persistence

  • Tissue localization studies comparing wild-type and pgi mutants

  • Evaluation of immune response to biofilm-associated bacteria

  • Testing efficacy of combination therapies targeting both metabolism and biofilms